Acurx Pharmaceuticals (ACXP) vs Enveric Biosciences (ENVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acurx Pharmaceuticals is the larger company by market cap ($6.9 million vs $6.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | ENVB |
|---|---|---|
| Share price | $1.25 | $1.44 |
| Market cap | $6.95M | $6.45M |
| 1-day change | 0.00% | -5.22% |
| EPS (TTM) | $-2.67 | $-13.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $13.25 |
| 52-week low | $1.23 | $1.17 |
| Distance from 52-week high | -84.34% | -89.13% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1260.00% | — |
| Average volume | 125.08K | 102.84K |
| Shares outstanding | 5.56M | 4.48M |
| Employees | 4 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Enveric Biosciences
ENVB stock →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ACXP vs ENVB FAQ
Which is bigger, Acurx Pharmaceuticals or Enveric Biosciences?
Acurx Pharmaceuticals (ACXP) is larger, with a market capitalization of $6.95M compared with $6.45M for Enveric Biosciences (ENVB).
Are Acurx Pharmaceuticals and Enveric Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.